CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX). Additionally, the two companies ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Anthropic co-founder Dario Amodei urges a deliberate slowdown in AI development, emphasizing ...

“Recursive self-improvement” is the idea that artificial intelligence could learn to build and train itself, creating exponential new progress — and risk. Jeff Clune, a computer scientist and ...

Earlier this year, Rishub Jain left his position as an artificial intelligence researcher at Google DeepMind after a revelation. As he worked on new models, he came to believe that he and everyone ...

From Philly and the Pa. suburbs to South Jersey and Delaware, what would you like WHYY News to cover? Let us know! Just shy of its 200th anniversary, the museum of the Academy of Natural Sciences of ...

The follow message was sent to Drexel and Academy of Natural Sciences communities: Dear Members of the Academy and Drexel Communities, Today we are sharing important news about the future of the ...

Plus: OpenAI has paused some model work over safety concerns. This is today's edition of The Download, our weekday newsletter that provides a daily dose of what's going on in the world of technology.

AI agents are not yet creative enough to carry out genuinely innovative open-ended AI research, it seems. The AI industry’s boldest promise right now is that AI will soon improve itself, with almost ...

The Television Academy welcomed a new class of industry heavyweights into its Hall of Fame on Thursday, honoring a diverse group of television trailblazers including Netflix co-CEO Ted Sarandos, ...

Recursion Pharmaceuticals, Inc. remains a Hold as competitive advances and slow revenue growth challenge its AI-driven drug discovery ambitions. RXRX's partnerships, notably with Genentech/Roche and ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

The up-to-$12 billion artificial intelligence (AI) drug discovery collaboration of Recursion, Roche, and its Genentech subsidiary marked a milestone Wednesday when plans were announced for Recursion ...